Cancer Immunotherapy

Priming the Immune System to Unleash Powerful and Targeted Attacks Against Cancer Cells


Immunotherapies are treatments that harness and activate the power of the immune system to fight disease.

The most significant obstacles historically facing successful development of effective cancer immunotherapies have been:

  • the difficulty of effectively presenting tumor antigens via the major histocompatibility complex (MHC) Class I pathway, which leads to effective priming of tumor-recognizing CD8+ killer T-cells;
  • the inability to concurrently stimulate the right immunological pathways to facilitate induction of critical chemokine and cytokines, which result in powerful anti-tumor CD8+ T-cell responses; and
  • the inability to overcome the tumor-development mechanisms to evade T-cell attack.

A successful cancer immunotherapy should also deliver a strong T-cell response capable of overcoming the tumor immuno-suppressive environment, to enable clinically beneficial anti-tumor immune responses.

At PDS, we are committed to developing more effective cancer immunotherapies. Our novel immunotherapy products, based on PDS’ proprietary Versamune® platform, directly enable efficient initiation of multiple important immunological processes. As a result of treatment with Versamune®-based products, we have proven that the immune system is able to generate a strong attack specifically against cancer cells, while simultaneously “de-camouflaging” those same cancer cells, making them even more susceptible to effective attack. Versamune®-based products present additional benefits of safety and simplicity, and are administered by a simple subcutaneous injection.

The immune system is designed to protect the body by detecting foreign agents and destroying abnormal cells which may develop into cancer, while at the same time preventing attack against healthy cells. In certain cases, cancer cells may co-opt the body’s regulatory mechanisms that prevent attack against healthy cells in order to suppress anti-cancer immune responses, or to “camouflage” itself in order to evade the immune system.

The ultimate goal of cancer immunotherapy is to overcome these mechanisms by which tumor cells are able to evade detection, and to also simultaneously prime the immune system to unleash a strong attack against cancerous cells by effectively generating sufficient quantities of potent tumor-targeting killer T-cells.

The Versamune® platform has demonstrated both in early human clinical trials and in extensive preclinical studies in multiple aggressive tumor models the ability to activate multiple steps in the immune response pathway: priming and induction of tumor-recognizing CD8+ T-cells, activation and proliferation of CD8+ T-cells through stimulation of type I interferon genes and minimizing the regulatory T-cell population to limit the cancer cells’ ability to evade attack.

PDS Biotechnology’s Versamune® platform presents a unique combination of potency and safety. This unusual characteristic of the Versamune®-based products presents unparalleled potential to significantly improve the effectiveness and safety of cancer treatment.

  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway One
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144